| Drug General Information |
| Drug ID |
D0Y9GK
|
| Former ID |
DNC007168
|
| Drug Name |
4-(4-aminophenyl)-1H-indazol-3yl-amine
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C13H12N4
|
| Canonical SMILES |
C1=CC(=C2C(=C1)NN=C2N)C3=CC=C(C=C3)N
|
| InChI |
1S/C13H12N4/c14-9-6-4-8(5-7-9)10-2-1-3-11-12(10)13(15)17-16-11/h1-7H,14H2,(H3,15,16,17)
|
| InChIKey |
KHQLSBOHZQJRPC-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
FL cytokine receptor |
Target Info |
Inhibitor |
[1]
|
|---|
| Mast/stem cell growth factor receptor |
Target Info |
Inhibitor |
[1]
|
| Vascular endothelial growth factor receptor 2 |
Target Info |
Inhibitor |
[1]
|
|
KEGG Pathway
|
Cytokine-cytokine receptor interaction
|
|
Hematopoietic cell lineage
|
|
Pathways in cancer
|
|
Transcriptional misregulation in cancer
|
|
Acute myeloid leukemia
|
|
Central carbon metabolism in cancerhsa04014:Ras signaling pathway
|
|
Rap1 signaling pathway
|
|
Endocytosis
|
|
PI3K-Akt signaling pathway
|
|
Melanogenesis
|
|
VEGF signaling pathway
|
|
Focal adhesion
|
|
Proteoglycans in cancer
|
|
NetPath Pathway
|
IL3 Signaling Pathway
|
|
IL4 Signaling Pathway
|
|
KitReceptor Signaling PathwayNetPath_14:IL2 Signaling Pathway
|
|
PANTHER Pathway
|
Angiogenesis
|
|
VEGF signaling pathway
|
|
Pathway Interaction Database
|
C-MYB transcription factor network
|
|
Signaling events mediated by Stem cell factor receptor (c-Kit)hif2pathway:HIF-2-alpha transcription factor network
|
|
Beta3 integrin cell surface interactions
|
|
Signaling events mediated by TCPTP
|
|
SHP2 signaling
|
|
S1P1 pathway
|
|
VEGF and VEGFR signaling network
|
|
Integrins in angiogenesis
|
|
Signaling events mediated by VEGFR1 and VEGFR2
|
|
Notch-mediated HES/HEY network
|
|
Reactome
|
PIP3 activates AKT signaling
|
|
Regulation of KIT signaling
|
|
Constitutive Signaling by Aberrant PI3K in Cancer
|
|
RAF/MAP kinase cascadeR-HSA-194306:Neurophilin interactions with VEGF and VEGFR
|
|
VEGF binds to VEGFR leading to receptor dimerization
|
|
Integrin cell surface interactions
|
|
EPHA-mediated growth cone collapse
|
|
VEGFA-VEGFR2 Pathway
|
|
VEGFR2 mediated cell proliferation
|
|
WikiPathways
|
Kit receptor signaling pathway
|
|
Differentiation Pathway
|
|
Signaling by SCF-KIT
|
|
PIP3 activates AKT signaling
|
|
Cardiac Progenitor Differentiation
|
|
miR-targeted genes in muscle cell - TarBase
|
|
miR-targeted genes in lymphocytes - TarBase
|
|
miR-targeted genes in epithelium - TarBaseWP306:Focal Adhesion
|
|
Nifedipine Activity
|
|
Signaling by VEGF
|
|
Angiogenesis
|
| References |
| REF 1 | J Med Chem. 2007 Apr 5;50(7):1584-97. Epub 2007 Mar 8.Discovery of N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea (ABT-869), a 3-aminoindazole-based orally active multitargeted receptor tyrosine kinase inhibitor. |
|---|
